Trans-activation of PPARα and induction of PPARα target genes by perfluorooctane-based chemicals

Toxicological Sciences

Volumn 80, Issue 1, 2004, Pages 151-160

  Shipley, Jonathan M ^a   Hurst, Christopher H ^a   Tanaka, Sue S ^b   DeRoos, Fred L ^b   Butenhoff, John L ^b   Seacat, Andrew M ^b   Waxman, David J ^a  

^a Boston University   (United States)

^b 3M COMPANY   (United States)

Author keywords

N ethyl perfluorooctanesulfonamidoethanol; Perfluorooctane sulfonate; Perfluorooctanesulfonamide; Peroxisome proliferation; PPAR; Rodent hepatocarcinogenesis

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; PERFLUOROOCTANE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SULFONIC ACID DERIVATIVE; ALKANESULFONIC ACID; FLUOROCARBON; LUCIFERASE; MESSENGER RNA; N ETHYL PERFLUOROOCTANESULFONAMIDO ETHANOL; N-ETHYL PERFLUOROOCTANESULFONAMIDO ETHANOL; PERFLUOROOCTANE SULFONIC ACID; PERFLUOROOCTANESULFONAMIDE; PEROXISOME PROLIFERATOR; SULFONAMIDE;

ANIMAL CELL; ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENE TARGETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR INTERACTION; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SOLUBILITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRANSACTIVATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL STRAIN COS1; CERCOPITHECUS; CHEMISTRY; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOUSE; POLYMERASE CHAIN REACTION; REPORTER GENE; TUMOR CELL LINE;

RODENTIA;

ALKANESULFONIC ACIDS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; FLUOROCARBONS; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; LUCIFERASES; MICE; PEROXISOME PROLIFERATORS; POLYMERASE CHAIN REACTION; PPAR ALPHA; RNA, MESSENGER; SOLUBILITY; SULFONAMIDES; TRANS-ACTIVATION (GENETICS);

EID: 3242806046     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/kfh130     Document Type: Article

References (43)

1. Bayly, A. C., French, N. J., Dive, C., and Roberts, R. A. (1993). Non-genotoxic hepatocarcinogenesis in vitro: The FaO hepatoma line responds to peroxisome proliferators and retains the ability to undergo apoptosis. J. Cell Sci. 104(Pt.2), 307-315.
2. Berthiaume, J., and Wallace, K. B. (2002). Perfluorooctanoate, perflourooctanesulfonate, and N-ethyl perfluorooctanesulfonamido ethanol; peroxisome proliferation and mitochondrial biogenesis. Toxicol. Lett. 129, 23-32.
3. Butenhoff, J. L., and Seacat, A. M. (2001). Comparative sub-chronic toxicity of perfluorooctanesulfonate (PFOS) and N-ethyl perfluoroctanesulfonamidoethanol (N-EtFOSE) in the rat. Toxicologist 60, 348 (Abstract 1655).
4. Cattley, R. C., DeLuca, J., Elcombe, C., Fenner-Crisp, P., Lake, B. G., Marsman, D. S., Pastoor, T. A., Popp, J. A., Robinson, D. E., Schwetz, B., Tugwood, J., and Wahli, W. (1998). Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul. Toxicol. Pharmacol. 27, 47-60.
5. Corton, J. C., Anderson, S. P., and Stauber, A. (2000). Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu. Rev. Pharmacol. Toxicol. 40, 491-518.
6. Forman, B. M., Chen, J., and Evans, R. M. (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. U. S.A. 94, 4312-4317.
7. Gibson, S. J., Johnson, J. D., and Ober, R. E., Eds. (1983). Absorption and biotransformation of N-ethyl FOSE and tissue distribution and elimination of carbon-14 after administration of N-ethyl FOSE-14 in feed. Riker Laboratories Ind., St. Paul, MN.
8. Giesy, J. P., and Kannan, K. (2001). Global distribution of perfluorooctane sulfonate in wildlife. Environ. Sci. Technol. 35, 1339-1342.
9. Gonzalez, F. J., Peters, J. M., and Cattley, R. C. (1998). Mechanism of action of the nongenotoxic peroxisome proliferators: Role of the peroxisome proliferator-activator receptor alpha. J. Natl. Cancer Inst. 90, 1702-1709.
10. Hansen, K. J., Clemen, L. A., Ellefson, M. E., and Johnson, H. O. (2001). Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. Environ. Sci. Technol. 35, 766-770.
11. Haughom, B., and Spydevold, O. (1992). The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim. Biophys. Acta 1128, 65-72.
12. Hsu, M. H., Palmer, C. N. A., Griffin, K. J., and Johnson, E. F. (1995). A single amino acid change in the mouse peroxisome proliferator-activated receptor alpha alters transcriptional responses to peroxisome proliferators. Molec. Pharmacol. 48, 559-567.
13. Hu, W., Jones, P. D., Upham, B. L., Trosko, J. E., Lau, C., and Giesy, J. P. (2002). Inhibition of gap junctional intercellular communication by perfluorinated compounds in rat liver and dolphin kidney epithelial cell lines in vitro and Sprague-Dawley rats in vivo. Toxicol. Sci. 68, 429-436.
14. Hurst, C. H., and Waxman, D. J. (2003). Activation of PPARalpha and PPAR-gamma by environmental phthalate monoesters. Toxicol. Sci. 74, 297-308.
15. Ikeda, T., Fukuda, K., Mori, I., Enomoto, M., Komai, T., and Suga, T. (1987). Induction of cytochrome P450 and peroxisome proliferation in rat liver by perfluorinated octanesulfonic acid. In Peroxisomes in Biology and Medicine (H. D. Fahimi and H. Sies, Eds.), pp. 304-308. Springer Verlag, New York.
16. Jounaidi, Y., Hecht, J. E. D., and Waxman, D. J. (1998). Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res. 58, 4391-401.
17. Keller, H., Devchand, P. R., Perroud, M., and Wahli, W. (1997). PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol. Chem. 378, 651-655.
18. Lake, B. G. (1995). Peroxisome proliferation: Current mechanisms relating to nongenotoxic carcinogenesis. Toxicol. Lett. 82-83, 673-681.
19. Lapinskas, P. J., and Corton, C. J. (1997). Peroxisome proliferator-activated receptor-alpha: Central mediator of peroxisome proliferator toxicity. CIIT Activities 17, 1-9.
20. Lock, E. A., Mitchell, A. M., and Elcombe, C. R. (1989). Biochemical mechanisms of induction of hepatic peroxisome proliferation. Annu. Rev. Pharmacol. Toxicol. 29, 145-163.
21. Luebker, D. J., Hansen, K. J., Bass, N. M., Buterhoff, J. L., and Seacat, A. M. (2002). Interactions of fluorochemicals with rat liver fatty acid-binding protein. Toxicology 176, 175-185.
22. MacKay, N. (1991). A Chemical History of 3M 1933-1990. The Bureau of Engraving, Minneapolis.
23. Maloney, E. K., and Waxman, D. J. (1999). trans-Activation of PPARalpha and PPARgamma by structurally diverse environmental chemicals. Toxicol. Appl. Pharmacol. 161, 209-218.
24. Moore, E. E., and Weiss, M. C. (1982). Selective isolation of stable and unstable dedifferentiated variants from a rat hepatoma cell line. J. Cell. Physiol. 111, 1-8.
25. Oliver, W. R., Jr., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., Xu, H. E., Sternbach, D. D., Kliewer, S. A., Hansen, B. C., and Willson, T. M. (2001). A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U.S.A. 98, 5306-5311.
26. Olsen, G. W., Burris, J. M., Mandel, J. H., and Zobel, L. R. (1999). Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. J. Occup. Environ. Med. 41, 799-806.
27. Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L., and Johnson, E. F. (1998). Peroxisome proliferator activated receptor-alpha expression in human liver. Mol. Pharmacol. 53, 14-22.
28. Peters, J. M., Cattley, R. C., and Gonzalez, F. J. (1997). Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy- 14,643. Carcinogenesis 18, 2029-2033.
29. Peters, J. M., Lee, S. S., Li, W., Ward, J. M., Gavrilova, O., Everett, C., Reitman, M. L., Hudson, L. D., and Gonzalez, F. J. (2000). Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol. Cell. Biol. 20, 5119-5128.
30. Roglans, N., Bellido, A., Rodriguez, C., Cabrero, A., Novell, F., Ros, E., Zambon, D., and Laguna, J. C. (2002). Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver. Clin. Pharmacol. Ther. 72, 692-701.
31. Rosen, E. D., and Spiegelman, B. M. (2000). Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: Ending the heartache. J. Clin. Invest. 106, 629-631.
32. Saez, E., Tontonoz, P., Nelson, M. C., Alvarez, J. G., Ming, U. T., Baird, S. M., Thomazy, V. A., and Evans, R. M. (1998). Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat. Med. 4, 1058-1061.
33. Schnellmann, R. G., and Manning, R. O. (1990). Perfluorooctane sulfonamide: A structurally novel uncoupler of oxidative phosphorylation. Biochim. Biophys. Acta 1016, 344-348.
34. Schoonjans, K., Staels, B., and Auwerx, J. (1996). The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1302, 93-109.
35. Seacat, A. M., Thomford, P. J., Hansen, K. J., Clemen, L. A., Eldridge, S. R., Elcombe, C. R., and Butenhoff, J. L. (2003). Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 183, 117-131.
36. Seacat, A. M., Thomford, P. J., Hansen, K. J., Olsen, G. W., Case, M. T., and Butenhoff, J. L. (2002). Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol. Sci. 68, 249-264.
37. Sohlenius, A. K., Andersson, K., and DePierre, J. W. (1992). The effects of perfluoro-octanoic acid on hepatic peroxisome proliferation and related parameters show no sex-related differences in mice. Biochem. J. 285, 779-783.
38. Starkov, A. A., and Wallace, K. B. (2002). Structural determinants of fluorochemical-induced mitochondrial dysfunction. Toxicol. Sci. 66, 244-252.
39. Vidal-Puig, A. J., Considine, R. V., Jimenez-Linan, M., Werman, A., Pories, W. J., Caro, J. F., and Flier, J. S. (1997). Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99, 2416-2422.
40. Wallace, K. B., Luebker, D. J., Butenhoff, J. L., and Seacat, A. M. (2001). Perfluorooctane sulfonate and 2-(N-ethylperfluorooctanesulfonamido)-ethyl alcohol are peroxisome proliferators in rats, but not guinea pigs. Toxicol. Sci. 60, 1657.
41. Xin, X., Yang, S., Kowalski, J., and Gerritsen, M. E. (1999). Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 274, 9116-9121.
42. Zhang, B., Marcus, S. L., Miyata, K. S., Subramani, S., Capone, J. P., and Rachubinski, R. A. (1993). Characterization of protein-DNA interactions within the peroxisome proliferator-responsive element of the rat hydratasedehydrogenase gene. J. Biol. Chem. 268, 12939-12945.
43. Zhou, Y. C., Davey, H. W., McLachlan, M. J., Xie, T., and Waxman, D. J. (2002). Elevated basal expression of liver peroxisomal beta-oxidation enzymes and CYP4A microsomal fatty acid w-hydroxylase in STAT5b-/- mice: Crosstalk in vivo between peroxisome proliferator-activated receptor and signal transducer and activator of transcription signaling pathways. Toxicol. Appl. Pharmacol. 182, 1-10.